S-F Lai1, C-W Wang, Y-H Chen, K-H Lan, J C-H Cheng, A-L Cheng, S-H Kuo. 1. Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Abstract
BACKGROUND AND PURPOSE: In this study, the clinical outcome and prognostic factors of adult medulloblastoma patients receiving multimodal treatment were investigated. PATIENTS AND METHODS: The clinical manifestations, treatment variables, and outcome of adult patients with medulloblastoma at our institution between 1983 and 2009 were retrospectively reviewed. RESULTS: A total of 20 adult patients were included (median age 22 years). Craniospinal irradiation (CSI) was given postoperatively. The craniospinal axis received a median of 30 Gy (range 23.4-39.6 Gy) in fractions of 1.6-2 Gy/day, and the tumor was boosted to a total median dose of 50 Gy (range 50-55.25 Gy). The 3-year disease-free survival (DFS) and overall survival (OS) rates for all patients were 45% and 50%, respectively. In univariate analysis, Karnofsky Performance Scale (KPS) > 70, neurologic symptoms duration > 30 days, lateral tumor location, standard risk patients, no hydrocephalus, radiotherapy (RT) treatment field (CSI + brain boost), and CSI dose ≥ 30 Gy were associated with better DFS. Standard-risk patients, RT treatment field (CSI + brain boost), and CSI dose ≥ 30 Gy were also significantly associated with better OS. CONCLUSION: The combined modality treatment results in a favorable outcome for adult medulloblastoma patients. Further investigation of the prognostic factors, radiation-related factors, and systemic chemotherapy is needed.
BACKGROUND AND PURPOSE: In this study, the clinical outcome and prognostic factors of adult medulloblastomapatients receiving multimodal treatment were investigated. PATIENTS AND METHODS: The clinical manifestations, treatment variables, and outcome of adult patients with medulloblastoma at our institution between 1983 and 2009 were retrospectively reviewed. RESULTS: A total of 20 adult patients were included (median age 22 years). Craniospinal irradiation (CSI) was given postoperatively. The craniospinal axis received a median of 30 Gy (range 23.4-39.6 Gy) in fractions of 1.6-2 Gy/day, and the tumor was boosted to a total median dose of 50 Gy (range 50-55.25 Gy). The 3-year disease-free survival (DFS) and overall survival (OS) rates for all patients were 45% and 50%, respectively. In univariate analysis, Karnofsky Performance Scale (KPS) > 70, neurologic symptoms duration > 30 days, lateral tumor location, standard risk patients, no hydrocephalus, radiotherapy (RT) treatment field (CSI + brain boost), and CSI dose ≥ 30 Gy were associated with better DFS. Standard-risk patients, RT treatment field (CSI + brain boost), and CSI dose ≥ 30 Gy were also significantly associated with better OS. CONCLUSION: The combined modality treatment results in a favorable outcome for adult medulloblastomapatients. Further investigation of the prognostic factors, radiation-related factors, and systemic chemotherapy is needed.
Authors: Stefan Rieken; Angela Mohr; Daniel Habermehl; Thomas Welzel; Katja Lindel; Olaf Witt; Andreas E Kulozik; Wolfgang Wick; Jürgen Debus; Stephanie E Combs Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-23 Impact factor: 7.038
Authors: C Carrie; C Lasset; C Alapetite; C Haie-Meder; S Hoffstetter; M C Demaille; C Kerr; J P Wagner; J L Lagrange; J P Maire Journal: Cancer Date: 1994-10-15 Impact factor: 6.860
Authors: M D Prados; R E Warnick; W M Wara; D A Larson; K Lamborn; C B Wilson Journal: Int J Radiat Oncol Biol Phys Date: 1995-07-15 Impact factor: 7.038
Authors: C Pfitzer; C-M Chen; T Wessel; T Keil; A Sörgel; T Langer; D Steinmann; A Borgmann-Staudt Journal: J Cancer Res Clin Oncol Date: 2014-05-20 Impact factor: 4.553
Authors: Michela Buglione; Paolo Ghirardelli; Luca Triggiani; Sara Pedretti; Nadia Pasinetti; Berardino De Bari; Sandro Tonoli; Paolo Borghetti; Luigi Spiazzi; Stefano Maria Magrini Journal: Rep Pract Oncol Radiother Date: 2015-04-08
Authors: Abhimanyu Ghose; John C Morris; John C Breneman; James Essell; Jiang Wang; Sadia Benzaquen Journal: J Investig Med High Impact Case Rep Date: 2014-04-17
Authors: D J Noble; T Ajithkumar; J Lambert; I Gleeson; M V Williams; S J Jefferies Journal: Clin Oncol (R Coll Radiol) Date: 2017-03-18 Impact factor: 4.126
Authors: Jiri Bartek; Sanjay Dhawan; Erik Thurin; Ali Alattar; Sasha Gulati; Bertil Rydenhag; Roger Henriksson; Clark C Chen; Asgeir Store Jakola Journal: J Neurooncol Date: 2020-05-19 Impact factor: 4.130